ATRA
Atara Biotherapeutics, Inc.
There isn't enough reported data to score ATRA yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ATRA Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Under pressure | |
| Strong |
ATRA's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ATRA PE Valuation
ATRA has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ATRA Forward outlook
There aren't enough analyst estimates for ATRA to show an outlook.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ATRA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$25.53 | +$44.22 |
| Q2 2024 | -$39.10 | +$34.65 |
| Q1 2024 | -$53.00 | -$0.75 |
| Q4 2023 | -$65.25 | -$9.25 |
| Q3 2023 | -$69.75 | -$8.00 |
| Q2 2023 | -$73.75 | -$10.00 |
| Q1 2023 | -$52.25 | +$38.75 |
| Q4 2022 | -$56.00 | +$34.75 |
ATRA has the stronger earnings trend. Trailing diluted EPS is down 106% for ATRA versus HIMS down 257%.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
ATRA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.2M | -65% |
| Q2 2026 | $630K | -96% |
| Q1 2026 | $516K | -99% |
| Q4 2025 | $1.6M | -95% |
| Q3 2025 | $3.5M | -91% |
| Q2 2025 | $17.6M | -39% |
| Q1 2025 | $98.1M | +259% |
| Q4 2024 | $32.8M | +670% |
ATRA's revenue has slid since its 2025 peak: $1M last quarter, down 65% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -243% | -139 points |
| Q2 2026 | -749% | -767 points |
| Q1 2026 | -653% | -692 points |
| Q4 2025 | -161% | -123 points |
| Q3 2025 | -104% | -49 points |
| Q2 2025 | 18% | +82 points |
| Q1 2025 | 40% | +154 points |
| Q4 2024 | -37% | +1373 points |
ATRA's operating margin was −243% last quarter, down 139 points from the same quarter a year ago.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over ATRA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over ATRA on profitability, with a higher operating margin.
ATRA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$879K | +$8.9M |
| Q2 2026 | -$3.3M | +$4M |
| Q1 2026 | -$3.1M | +$25.1M |
| Q4 2025 | -$5.7M | +$18.9M |
| Q3 2025 | -$9.8M | -$5.8M |
| Q2 2025 | -$7.3M | +$3.4M |
| Q1 2025 | -$28.1M | +$1.6M |
| Q4 2024 | -$24.6M | +$25.9M |
ATRA has burned cash in almost every quarter: −$13M over the past year, against −$70M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over ATRA on cash generation, producing positive trailing cash flow while its opponent burns cash.
ATRA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.9% | +293K shares |
| 1 year | +25% | +3M shares |
| 3 years | +269% | +11.2M shares |
| 5 years | +319% | +11.7M shares |
| Available history | +647% | +13.3M shares |
ATRA has 15M diluted shares, up 25% from a year ago.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ATRA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ATRA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | -0.2x | Net Cash |
| Q3 2025 | -0.2x | Net Cash |
| Q2 2025 | -1.4x | Net Cash |
ATRA has more cash than debt.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has the edge over ATRA on leverage, with a lower net debt burden relative to earnings.
ATRA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.3 | Neutral |
| Stochastic | 12.7 | Oversold |
ATRA's weekly RSI is 44 (neutral) and its Stochastic is 13 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ATRA PE vs Healthcare Sector
ATRA has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ATRA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $8.67 | 8.5% below |
| 20 week MA | $8.98 | 12% below |
| 50 week MA | $8.74 | 9.3% below |
| 100 week MA | $9.48 | 16% below |
| 200 week MA | $21.2 | 63% below |
ATRA is in a downtrend: it's below all five of its weekly moving averages, and 63% below its 200-week average.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ATRA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $412.8 | $554.5 | +34% |
| 2021 | $554.5 | $432.8 | -22% |
| 2022 | $432.8 | $74.8 | -83% |
| 2023 | $74.8 | $12.8 | -83% |
| 2024 | $12.8 | $12.2 | -5.2% |
| 2025 | $12.2 | $17.3 | +42% |
| 2026 YTD | $17.3 | $7.93 | -54% |
ATRA has finished lower in four of the last six years. It's down 54% so far in 2026.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over ATRA on returns for 2026, with the stronger performance.